Literature DB >> 17728023

Long lasting BCG protection against leprosy.

Laura Cunha Rodrigues1, Ligia Regina Sansigolo Kerr-Pontes, Max Victor Carioca Frietas, Maurício Lima Barreto.   

Abstract

BACKGROUND: BCG vaccine protects against leprosy.
OBJECTIVES: Estimate BCG protection against leprosy by age by age.
METHODS: A case control study with 226 cases of leprosy and 857 controls. BCG vaccination was ascertained via examination of BCG scars. Protection is presented for three age groups.
RESULTS: BCG protection against leprosy was 86% (95% CI: 77-92%) in the age group 18-29; 54% (95% CI: -37% to 85%) in the age group 30-39 and 32% (95% CI: -3% to 56%) in those aged 40 or more.
CONCLUSIONS: BCG efficacy against leprosy may well last for three decades and possibly even longer. BCG vaccination must have contributed to worldwide reduction in leprosy incidence.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17728023     DOI： 10.1016/j.vaccine.2007.07.032

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

2.  Pathogenesis and Host Immune Response in Leprosy.

Authors:  Hadida Yasmin; Praveen Mathews Varghese; Sanjib Bhakta; Uday Kishore
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  The State of Affairs in Post-Exposure Leprosy Prevention: A Descriptive Meta-Analysis on Immuno- and Chemo-Prophylaxis.

Authors:  Anne Schoenmakers; Liesbeth Mieras; Teky Budiawan; Wim H van Brakel
Journal:  Res Rep Trop Med       Date:  2020-10-15

4.  Proteomic profile of culture filtrate from the Brazilian vaccine strain Mycobacterium bovis BCG Moreau compared to M. bovis BCG Pasteur.

Authors:  Marcia Berrêdo-Pinho; Dario E Kalume; Paloma R Correa; Leonardo H F Gomes; Melissa P Pereira; Renata F da Silva; Luiz R R Castello-Branco; Wim M Degrave; Leila Mendonça-Lima
Journal:  BMC Microbiol       Date:  2011-04-20       Impact factor: 3.605

5.  Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.

Authors:  Alexandra G Fraga; Teresa G Martins; Egídio Torrado; Kris Huygen; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  PLoS One       Date:  2012-03-08       Impact factor: 3.240

Review 6.  Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.

Authors:  Malcolm S Duthie; Marivic F Balagon
Journal:  Risk Manag Healthc Policy       Date:  2016-04-27

7.  Interruption of persistent exposure to leprosy combined or not with recent BCG vaccination enhances the response to Mycobacterium leprae specific antigens.

Authors:  Fernanda Marques de Carvalho; Luciana Silva Rodrigues; Nádia Cristina Duppre; Iris Maria Peixoto Alvim; Marcelo Ribeiro-Alves; Roberta Olmo Pinheiro; Euzenir Nunes Sarno; Maria Cristina Vidal Pessolani; Geraldo Moura Batista Pereira
Journal:  PLoS Negl Trop Dis       Date:  2017-05-03

8.  Widespread nasal carriage of Mycobacterium lepraeamong a healthy population in a hyperendemic region of northeastern Brazil.

Authors:  Luana Nepomuceno Gondim Costa Lima; Cristiane Cunha Frota; Rosa Maria Salani Mota; Rosa Livia Freitas Almeida; Maria Araci de Andrade Pontes; Heitor de Sá Gonçalves; Laura Cunha Rodrigues; Carl Kendall; Ligia Kerr
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-11       Impact factor: 2.743

9.  Bacillus of Calmette and Guérin (BCG) and the risk of leprosy in Ciudad del Este, Paraguay, 2016-2017.

Authors:  Nancy Carolina Cuevas; Victor M Cardenas
Journal:  Epidemiol Health       Date:  2021-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.